Role of some circulating MiRNAs on breast cancer diagnosis

Abstract

Aberrant expression of miRNAs has a link with tumorgenesis and their deregulation is reported in biological fluids of cancer patients. Authors aimed to investigate the diagnostic role of miRNA-17-5p, miR-155 and miRNA-222 in serum samples from breast cancer patients (n = 80), benign breast patients (n = 40) and healthy individuals (n = 30) using quantitative real-time PCR technique. Median levels of investigated markers revealed significant increase in primary breast cancer followed by benign and control groups. Investigated miRNAs reported significant relation with clinical stages and histological grading, while only miRNA-17-5p showed significant relation with hormone receptors. When considering investigated miRNAs as compared to tumor marker, their sensitivities were superior over tumor markers for early diagnosis of breast cancer, detection of early stages and low grades breast cancer patients. In conclusion, detection of the miRNA-17-5p, miR-155 and miRNA-222 expression levels in serum samples is significant promising molecular markers for early breast cancer diagnosis.

Clinical Translatability of “Identified” Circulating miRNAs for Diagnosing Breast Cancer: Overview and Update

“…An in-depth analysis of the data suggested that circulating miRNAs were identified as potential diagnostic biomarkers for BC lacked specificity and often showed discordant expression in the blood and tissue of patients affected with cancer. The final processing of our in-depth analysis revealed that a circulating miRNA signature for BC diagnosis is currently unavailable because the most frequently studied circulating miRNA, BC-associated miRNAs (miR-155, miR-21, miR-195, and miR-145), except for miR-195, are the most non-specific BC-associated miRNAs, although some of these miRNAs were able to discriminate patients with BC from patients with benign breast lesions (BBLs) (miR-21 [69,78]; miR-155 [79,80]; miR-145 and miR-195 [61]). Factors triggering neoplastic transformation may differ among tumors, but the common denominator for all neoplastic diseases is uncontrolled cell growth and the activation of inflammatory processes.…”

Clinical Impact of Oncomirs 221 and 222 on Breast Cancer Diagnosis

“…Several recent studies have demonstrated that miRNAs are stably detectable in plasma/serum [28,29,30]. MiRNA-221 and miRNA-222 are overexpressed in different types of malignant neoplasms including ovarian cancer 31, hepatocellular cancer [32], glioblastomas [33] and breast cancer [10,13,34]. Both miRNAs were shown to promote cell growth, cell cycle progression and invasion in these tumore types in vitro and in vivo [32,33].…”

“…MicroRNAs (miRNAs) are a family of highly conserved noncoding single stranded RNA molecules of 21 to 25 nucleotides; It is can regulate one third of protein-coding genes and participate in the developmental and physiological processes of human body [9]. Aberrant expression of miRNAs has a link with breast tumorgenesis and their deregulation is reported in biological fluids of cancer patients [10]. MiRNAs have important regulatory roles in the cell; modulate their target genes through RNA interference pathways (RNAi).…”

Expressão de miRNAs como fator de predição de resposta a quimioterapia primária em pacientes com câncer de mama

“…A associação entre pCR e melhora da sobrevida parece estar restrito à alguns subtipos moleculares do câncer de mama (DÍAZ-CASAS et al, 2019;FIROUZABADI et al, 2019;HARBECK;GNANT, 2017). (FERRACIN et al, 2015;LÜ et al, 2017;SWELLAM et al, 2018b;ZHU et al, 2018 HU et al, 2018;LI et al, 2017;MISHRA et al, 2015;YAMADA et al, 2018 direta entre a desregulação dos miRNAs e a progressão tumoral (SWELLAM et al, 2018b;ZHU et al, 2018).…”

“…Os miRNAs regulam inúmeras vias do câncer, promovendo proliferação, invasão e metástase (HU et al, 2018;IWASAKI et al, 2015;LI et al, 2017;SWELLAM et al, 2018b…”